How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

1. Diabetes and Cardiovascular Risk in Renal Transplant Patients.International journal of molecular sciences · 2021
   Review
2. Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
   Article
3. Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.Diabetes, obesity & metabolism · 2019
   Article
4. Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice.Diabetes spectrum : a publication of the American Diabetes Association · 2019
   Article
5. Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons.European endocrinology · 2018
   Review
6. Use of V-GoDiabetes therapy : research, treatment and education of diabetes and related disorders · 2015
   Article
7. Diabetes Mellitus and Prediabetes on Kidney Transplant Waiting List- Prevalence, Metabolic Phenotyping and Risk Stratification Approach.PloS one · 2015
   Article
8. Metformin inhibits the proliferation of A549/CDDP cells by activating p38 mitogen-activated protein kinase.Oncology letters · 2014
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as